FDA says current dose of GSK-Vir Covid therapy unlikely to work against BA.2 variant

The U.S. health regulator has determined that the current authorized dose of GlaxoSmithKline Plc and Vir Biotechnology’s antibody-based COVID-19 treatment is unlikely to be effective against the Omicron BA.2 variant, the companies said on Friday.

The agency updated its emergency use authorization fact sheet on the drug sotrovimab. WTVB